tetano
Editor, Senior Moderator
J Clin Invest
. 2021 Aug 19;151697.
doi: 10.1172/JCI151697. Online ahead of print.
Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19
Ravindra Ganesh[SUP] 1 [/SUP], Colin F Pawlowski[SUP] 2 [/SUP], John C O'Horo[SUP] 3 [/SUP], Lori L Arndt[SUP] 4 [/SUP], Richard F Arndt[SUP] 5 [/SUP], Sarah Bell[SUP] 6 [/SUP], Dennis M Bierle[SUP] 1 [/SUP], Molly Destro Borgen[SUP] 7 [/SUP], Sara Hanson[SUP] 8 [/SUP], Alexander Heyliger[SUP] 9 [/SUP], Jennifer L Larsen[SUP] 6 [/SUP], Patrick J Lenehan[SUP] 10 [/SUP], Robert Orenstein[SUP] 11 [/SUP], Arjun Puranik[SUP] 2 [/SUP], Leigh L Speicher[SUP] 12 [/SUP], Sidna M Tulledge-Scheitel[SUP] 13 [/SUP], A J Venkatakrishnan[SUP] 2 [/SUP], Caroline G Wilker[SUP] 14 [/SUP], Andrew D Badley[SUP] 3 [/SUP], Raymund R Razonable[SUP] 15 [/SUP]
Affiliations
Abstract
Background: Clinical data to support the use of bamlanivimab for the treatment of outpatients with mild to moderate coronavirus disease-19 (COVID-19) is needed.
Methods: 2,335 patients who received single-dose bamlanivimab infusion between November 12, 2020 to February 17, 2021 were compared with a propensity-matched control of 2,335 untreated patients with mild to moderate COVID-19 at Mayo Clinic facilities across 4 states. The primary outcome was the rate of hospitalization at days 14, 21 and 28.
Results: The median age of the population was 63; 47.3% of the bamlanivimab-treated cohort were ≥65 years; 49.3% were female. High-risk characteristics included hypertension (54.2%), body mass index ≥35 (32.4%), diabetes mellitus (26.5%), chronic lung disease (25.1%), malignancy (16.6%), and renal disease (14.5%). Patients who received bamlanivimab had lower all-cause hospitalization rates at days 14 (1.5% vs 3.5%; Odds Ratio [OR], 0.38), 21 (1.9% vs 3.9%; OR, 0.46), and 28 (2.5% vs 3.9%; OR, 0.61). Secondary exploratory outcomes included lower intensive care unit admission rates at days 14 (0.14% vs 1%; OR, 0.12), 21 (0.25% vs 1%; OR: 0.24) and 28 (0.56% vs 1.1%; OR: 0.52), and lower all-cause mortality at days 14 (0% vs 0.33%), 21 (0.05% vs 0.4%; OR,0.08) and 28 (0.11% vs 0.44%; OR, 0.01). Adverse events were uncommon with bamlanivimab, occurring in 19/2355, most commonly fever (n=6), nausea (n=5), and lightheadedness (n=3).
Conclusions: Among high-risk patients with mild to moderate COVID-19, treatment with bamlanivimab was associated with a statistically significant lower rate of hospitalization compared with usual care.
Funding: Mayo Clinic. .
Keywords: Drug therapy; Virology.
. 2021 Aug 19;151697.
doi: 10.1172/JCI151697. Online ahead of print.
Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19
Ravindra Ganesh[SUP] 1 [/SUP], Colin F Pawlowski[SUP] 2 [/SUP], John C O'Horo[SUP] 3 [/SUP], Lori L Arndt[SUP] 4 [/SUP], Richard F Arndt[SUP] 5 [/SUP], Sarah Bell[SUP] 6 [/SUP], Dennis M Bierle[SUP] 1 [/SUP], Molly Destro Borgen[SUP] 7 [/SUP], Sara Hanson[SUP] 8 [/SUP], Alexander Heyliger[SUP] 9 [/SUP], Jennifer L Larsen[SUP] 6 [/SUP], Patrick J Lenehan[SUP] 10 [/SUP], Robert Orenstein[SUP] 11 [/SUP], Arjun Puranik[SUP] 2 [/SUP], Leigh L Speicher[SUP] 12 [/SUP], Sidna M Tulledge-Scheitel[SUP] 13 [/SUP], A J Venkatakrishnan[SUP] 2 [/SUP], Caroline G Wilker[SUP] 14 [/SUP], Andrew D Badley[SUP] 3 [/SUP], Raymund R Razonable[SUP] 15 [/SUP]
Affiliations
- PMID: 34411003
- DOI: 10.1172/JCI151697
Abstract
Background: Clinical data to support the use of bamlanivimab for the treatment of outpatients with mild to moderate coronavirus disease-19 (COVID-19) is needed.
Methods: 2,335 patients who received single-dose bamlanivimab infusion between November 12, 2020 to February 17, 2021 were compared with a propensity-matched control of 2,335 untreated patients with mild to moderate COVID-19 at Mayo Clinic facilities across 4 states. The primary outcome was the rate of hospitalization at days 14, 21 and 28.
Results: The median age of the population was 63; 47.3% of the bamlanivimab-treated cohort were ≥65 years; 49.3% were female. High-risk characteristics included hypertension (54.2%), body mass index ≥35 (32.4%), diabetes mellitus (26.5%), chronic lung disease (25.1%), malignancy (16.6%), and renal disease (14.5%). Patients who received bamlanivimab had lower all-cause hospitalization rates at days 14 (1.5% vs 3.5%; Odds Ratio [OR], 0.38), 21 (1.9% vs 3.9%; OR, 0.46), and 28 (2.5% vs 3.9%; OR, 0.61). Secondary exploratory outcomes included lower intensive care unit admission rates at days 14 (0.14% vs 1%; OR, 0.12), 21 (0.25% vs 1%; OR: 0.24) and 28 (0.56% vs 1.1%; OR: 0.52), and lower all-cause mortality at days 14 (0% vs 0.33%), 21 (0.05% vs 0.4%; OR,0.08) and 28 (0.11% vs 0.44%; OR, 0.01). Adverse events were uncommon with bamlanivimab, occurring in 19/2355, most commonly fever (n=6), nausea (n=5), and lightheadedness (n=3).
Conclusions: Among high-risk patients with mild to moderate COVID-19, treatment with bamlanivimab was associated with a statistically significant lower rate of hospitalization compared with usual care.
Funding: Mayo Clinic. .
Keywords: Drug therapy; Virology.